Compared with existing PD‐L1 antibodies or small‐molecule inhibitors, PTPR peptides regulate PD‐L1 protein levels by targeting TMUB1‐PD‐L1 interactions, potentially circumventing tolerance issues caused by PD‐L1 translocation in conventional ICB therapy.[14] The fluorination modification strategy used in this study improved the lysosomal release of the peptides and preserved their biological activity within the complex tumor microenvironment. Here, TMUB1 is linked to neoplasm.